A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

Inclusion Criteria:

• Cohort 1: Patients with histologically confirmed epithelial ovarian cancer, fallopiantube, or primary peritoneal cancer subjects with any high-grade serous component,progressed on or after platinum-containing therapy and not eligible for furtherplatinum containing treatment (platinum-resistant, platinum-refractory disease definedby progression of disease on a platinum-containing regimen or recurrence of diseasewithin 180 days of receiving the last dose of platinum-based treatment).
• Cohort 2: Patients with selected tumor types that have relapsed or progressed after 2lines of therapy or who are ineligible for other standard of care (SOC) therapies:

1. Histologically or cytologically confirmed metastatic NSCLC
2. Histologically or cytologically confirmed recurrent or metastatic HNSCC (oralcavity, oropharynx, hypopharynx, or larynx)
3. Histologically or cytologically confirmed metastatic or non-resectable advancedmetastatic gastric or gastroesophageal adenocarcinoma
4. Histologically or cytologically confirmed unresectable, locally advanced ormetastatic TNBC (confirmed HER2-negative, estrogen receptor-negative andprogesterone receptor-negative)
5. Histologically confirmed ovarian cancer of all high-grade epithelial types whoare IO treatment naïve and have progressed after 3 months on or afterplatinum-containing therapy
6. PD-L1 expression Tumor Proportion Score (TPS) ≥ 1% for NSCLC and CombinedProportion Score (CPS) ≥ 1% for all other tumor types
7. A 28-day washout period after the completion of programmed death-1 (PD-1)/PD-L1therapy
8. Patients should have no more than 5 prior lines of therapies

• Cohort 2 - (Optional for the ovarian cohort) Pre-treatment fresh tumor biopsies andpaired treatment fresh tumor biopsies will be collected from at least 5 patients.Biopsy must be excisional, incisional, or core.

Exclusion Criteria:

• Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or withan agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX 40 [Tumor necrosis factorreceptor superfamily, member 4 (TNFRSF4)], CD137 [tumor necrosis factor receptorsuperfamily member 9 (TNFRSF9)]) (only applies to ovarian cancer patients in Cohorts 1and 2)
• Disease progression within 6 months of starting anti-PD-1 and anti-PD-L1 inhibitors
• Known active or chronic Hepatitis B or Hepatitis C, other hepatitides (non-alcoholsteatohepatitis, alcohol or drug-related, autoimmune) serology at screening orcirrhosis
• Active autoimmune disease requiring systemic treatment within the past 12 months
• Active interstitial lung disease (ILD) or pneumonitis or a history of ILD
• Brain involvement with cancer, spinal cord compression, carcinomatous meningitis, ornew evidence of brain or leptomeningeal disease; unless the lesion(s) have beenradiated or resected, are considered fully treated and inactive, are asymptomatic, andno steroids have been administered for CNS disease over the 7 days prior to studytreatment
• Angina, myocardial infarction (MI), symptomatic congestive heart failure,cerebrovascular accident, transient ischemic attack TIA), arterial embolism, pulmonaryembolism, percutaneous transluminal coronary angioplasty (PTCA), or coronary arterybypass grafting (CABG) within 6 months prior to study treatment
• Known human immunodeficiency virus (HIV) unless CD4+ T cell count > 350 cells/μL withan undetectable viral load